Filtros de búsqueda

Lista de obras de

18 F-FDG PET Early After Radiotherapy in Lymphoma Patients

18F-FDG PET early after radiotherapy in lymphoma patients

artículo científico publicado en 2004

A critical history of chromic myeloid leukemia

artículo científico publicado en 2014

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

artículo científico publicado en 2002

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

artículo científico publicado en 2008

A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

artículo científico publicado en 2007

A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia

artículo científico publicado en 2011

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

artículo científico publicado en 2016

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

artículo científico publicado en 2007

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

artículo científico publicado en 2002

A review of the European LeukemiaNet recommendations for the management of CML.

artículo científico

A risk prediction score for invasive mold disease in patients with hematological malignancies

artículo científico publicado en 2013

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

article by Simona Soverini et al published 20 June 2005 in Journal of Clinical Oncology

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

artículo científico publicado en 2011

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

artículo científico publicado en 2006

Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation

artículo científico publicado en 2004

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

artículo científico publicado en 2012

Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia

artículo científico publicado en 2006

Advances in the treatment for haematological malignancies

artículo científico publicado en 2006

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis

artículo científico

Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant

Amifostine feasibility and efficacy in autologous stem cell transplantation for multiple myeloma.

artículo científico publicado en 2004

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases

artículo científico publicado en 2003

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

artículo científico publicado en 2004

Assessment of Minimal Residual Disease in Standard-Risk AML

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

artículo científico publicado en 2012

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts

artículo científico publicado en 2003

Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.

artículo científico publicado en 2009

Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization

B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.

artículo científico publicado en 2010

B-cell compartment as the selective target for the treatment of immune thrombocytopenias

artículo científico publicado el 1 de mayo de 2003

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

artículo científico publicado en 2002

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

artículo científico publicado en 2011

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

artículo científico publicado en 2014

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

artículo científico publicado en 2012

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

artículo científico publicado en 2010

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

scientific article published on 27 February 2012

Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma

artículo científico publicado en 2007

CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.

artículo científico publicado en 2011

Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

artículo científico publicado el 17 de marzo de 2011

Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.

artículo científico publicado en 2004

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

artículo científico publicado en 2011

Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications

artículo científico publicado en 2010

Chronic myeloid leukaemia

artículo científico publicado en 2007

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

artículo científico

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.

artículo científico publicado en 2009

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

artículo científico publicado en 2009

Chronic myeloid leukemia: room for improvement?

artículo científico publicado en 2017

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

artículo científico publicado en 2011

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

artículo científico publicado en 2006

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

artículo científico publicado en 2009

Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient

artículo científico publicado en 2010

Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature

artículo científico publicado en 2003

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

artículo científico publicado en 2015

Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies.

artículo científico publicado en 2012

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

artículo científico publicado en 2012

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

artículo científico publicado en 2016

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

artículo científico publicado en 2017

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

artículo científico

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

artículo científico publicado en 2003

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma

artículo científico publicado en 2009

Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments

artículo científico publicado en 2012

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

artículo científico publicado en 2010

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

artículo científico publicado en 2011

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

artículo científico publicado en 2006

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

artículo científico publicado en 2011

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

artículo científico publicado en 2010

Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.

artículo científico publicado en 2012

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

artículo científico publicado en 2002

Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

artículo científico

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

artículo científico

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

artículo científico publicado en 2010

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

artículo científico publicado en 2004

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

artículo científico publicado en 2002

Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes

artículo científico publicado en 2006

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

artículo científico publicado en 2010

Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns

artículo científico publicado en 2007

Diagnosis of bloodstream infections in immunocompromised patients by real-time PCR.

artículo científico publicado en 2009

Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia

artículo científico publicado en 2003

Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.

artículo científico publicado en 2005

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

artículo científico publicado en 2004

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients

article by Pier Luigi Zinzani et al published January 2012 in European Journal of Nuclear Medicine and Molecular Imaging

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

artículo científico publicado en 2013

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study

artículo científico publicado en 2013

Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma

artículo científico publicado en 2004

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas

artículo científico publicado en 2005

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

artículo científico publicado en 2003

Efficacy of thalidomide in the treatment of myelodysplastic syndromes.

artículo científico publicado en 2002

Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.

artículo científico publicado en 2009

Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase

artículo científico publicado en 2004

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

artículo científico publicado en 2013

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

artículo científico publicado en 2006

Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage

artículo científico publicado en 2002

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

artículo científico publicado en 2008

Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo

artículo científico publicado en 2004

Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients

artículo científico publicado en 2003

Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens

artículo científico publicado en 2012

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

artículo científico publicado en 2016

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

artículo científico publicado en 2015

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

artículo científico publicado en 2004

First-line therapy for chronic myeloid leukemia: new horizons and an update

artículo científico publicado en 2010

First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

artículo científico publicado en 2004

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

artículo científico publicado en 2006

First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies

artículo científico

Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial

artículo científico publicado en 2018

Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study

artículo científico publicado en 2003

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

artículo científico publicado en 2008

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

artículo científico publicado en 2004

Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma

artículo científico publicado en 2004

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

artículo científico publicado en 2008

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

GVHD and prognostic factors

artículo científico publicado en 2006

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

artículo científico publicado en 2005

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

artículo científico publicado en 2004

Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets

artículo científico publicado en 2007

Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells

article

Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti‐idiotype vaccination

artículo científico publicado el 1 de abril de 2003

Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy

artículo científico publicado en 2004

Hairy cell leukemia: evaluation of the long-term outcome in 121 patients

artículo científico publicado en 2010

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

artículo científico publicado en 2011

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib

artículo científico publicado en 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

artículo científico publicado en 2002

High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience

artículo científico publicado en 2004

Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

artículo científico publicado en 2007

Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade

artículo científico publicado en 2003

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.

artículo científico publicado en 2012

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

artículo científico publicado en 2012

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

artículo científico publicado en 2009

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

artículo científico publicado en 2009

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

article published in 2008

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

artículo científico publicado en 2016

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2004

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

artículo científico publicado en 2003

Imatinib in chronic myeloid leukemia elderly patients

artículo científico publicado el 1 de diciembre de 2011

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

artículo científico publicado en 2002

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

artículo científico publicado en 2004

Imatinib mesylate for the treatment of chronic myeloid leukemia

artículo científico publicado en 2008

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

artículo científico publicado en 2005

Imatinib mesylate in the treatment of hematologic malignancies

artículo científico publicado en 2007

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study

artículo científico publicado en 2007

Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients

artículo científico publicado en 2010

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

artículo científico publicado en 2013

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

artículo científico publicado en 2016

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

artículo científico publicado en 2016

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

artículo científico publicado en 2015

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

artículo científico publicado en 2008

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease

artículo científico publicado en 2008

Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells

artículo científico publicado en 2010

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results

artículo científico publicado en 2009

Interferon-alfa for chronic myeloid leukemia

artículo científico publicado en 2003

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.

artículo científico publicado en 2009

Interleukin-11 induces proliferation of human T-cells and its activity is associated with downregulation of p27(kip1)

artículo científico publicado en 2002

Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells

article

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

artículo científico publicado en 2008

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

artículo científico publicado en 2013

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

artículo científico publicado en 2009

Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

artículo científico publicado en 2008

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

artículo científico publicado en 2017

Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy

artículo científico publicado en 2009

Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients

artículo científico publicado en 2010

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

artículo científico publicado en 2007

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

artículo científico publicado en 2008

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

artículo científico publicado en 2014

Low-dose rituximab in adult patients with primary immune thrombocytopenia

artículo científico publicado en 2010

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

artículo científico publicado en 2011

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

artículo científico publicado en 2008

Management of pregnant chronic myeloid leukemia patients

artículo científico publicado en 2016

Managing children with chronic myeloid leukaemia

artículo científico publicado en 2014

Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study

artículo científico publicado en 2002

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma

artículo científico publicado en 2010

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

artículo científico publicado en 2011

Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection.

artículo científico publicado en 2006

Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells

artículo científico publicado en 2007

Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia

artículo científico publicado en 2008

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib

artículo científico publicado en 2009

Molecular monitoring

artículo científico publicado en 2014

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor

artículo científico

Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia

artículo científico publicado en 2013

Molecular response in CML: where is the bar?

artículo científico publicado en 2014

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

artículo científico publicado en 2003

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio

artículo científico publicado en 2007

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

artículo científico publicado en 2006

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

artículo científico publicado en 2006

Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells

artículo científico publicado en 2008

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

artículo científico publicado en 2002

Monitoring treatment of chronic myeloid leukemia

artículo científico publicado en 2008

Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden

artículo científico publicado en 2014

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

artículo científico publicado en 2005

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

artículo científico publicado en 2005

New directions in the treatment of patients with chronic myeloid leukemia: introduction.

artículo científico publicado en 2009

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment

artículo científico publicado en 2016

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2014

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

artículo científico publicado en 2016

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

artículo científico publicado en 2007

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia

article

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

artículo científico publicado en 2015

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

artículo científico publicado en 2010

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

article

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

artículo científico publicado en 2007

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2017

Nonsecretory Multiple Myeloma

Nuclear factor kB as a target for new drug development in myeloid malignancies

artículo científico publicado en 2007

Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells

artículo científico publicado en 2005

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

artículo científico publicado en 2013

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

artículo científico publicado en 2014

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia

artículo científico publicado en 2008

P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia.

artículo científico publicado en 2002

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

artículo científico publicado en 2009

Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera

artículo científico publicado en 2007

Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia

artículo científico publicado en 2013

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

artículo científico publicado en 2015

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

article by Antonio Curti et al published November 2007 in British Journal of Haematology

Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients

artículo científico publicado en 2005

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

artículo científico publicado en 2007

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients

artículo científico publicado en 2010

Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.

artículo científico publicado en 2005

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

artículo científico publicado en 2009

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

artículo científico publicado en 2010

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

artículo científico publicado en 2009

Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias

artículo científico publicado en 2005

Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.

artículo científico publicado en 2008

Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.

artículo científico publicado en 2011

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

artículo científico publicado en 2017

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

artículo científico publicado en 2012

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

artículo científico publicado en 2018

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

artículo científico publicado en 2016

Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation

Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

artículo científico publicado en 2011

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.

artículo científico publicado en 2007

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

artículo científico publicado en 2008

Primary bone lymphoma: experience with 52 patients

artículo científico publicado en 2003

Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion.

artículo científico publicado en 2006

Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

artículo científico publicado en 2013

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

artículo científico publicado en 2011

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

article by Michele Cavo et al published 10 June 2007 in Journal of Clinical Oncology

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies

artículo científico publicado en 2016

Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice.

artículo científico publicado en 2011

Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma

artículo científico publicado en 2005

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

artículo científico publicado en 2003

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

artículo científico publicado en 2009

Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters.

artículo científico publicado en 2006

Response definitions and European Leukemianet Management recommendations

artículo científico publicado en 2009

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

artículo científico publicado en 2011

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

artículo científico publicado en 2009

Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia

artículo científico publicado en 2003

Rituximab for the treatment of type II mixed cryoglobulinemia

scholarly article by Francesco Zaja et al published August 2002 in Arthritis and Rheumatism

Rituximab in heavily pretreated cutaneous B-cell lymphoma

artículo científico publicado en 2003

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

artículo científico publicado en 2008

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

artículo científico publicado en 2009

Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency

artículo científico publicado en 2012

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma

artículo científico publicado en 2002

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

artículo científico publicado en 2011

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

artículo científico publicado en 2009

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

scientific article published on 09 February 2011

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

article by Simona Soverini et al published March 2007 in Lancet Oncology Commission

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

artículo científico publicado en 2009

Sinonasal Risk Factors for the Development of Invasive Fungal Sinusitis in Hematological Patients: Are they Important?

artículo científico publicado el 1 de enero de 2011

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission

artículo científico publicado en 2004

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

artículo científico publicado en 2013

Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia

artículo científico publicado en 2009

Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia

artículo científico publicado en 2004

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B

scientific article published in 2006

Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline

artículo científico publicado en 2007

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

artículo científico publicado en 2005

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

artículo científico publicado en 2017

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

artículo científico publicado en 2004

Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency

artículo científico publicado en 2010

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

The CD47 pathway is deregulated in human immune thrombocytopenia

artículo científico publicado en 2011

The European LeukemiaNet: achievements and perspectives

artículo científico publicado en 2010

The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party

artículo científico publicado en 2010

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients

artículo científico publicado en 2004

The changing landscape of myeloma therapy

artículo científico publicado en 2006

The cytogenetic response as a surrogate marker of survival

artículo científico publicado en 2003

The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

artículo científico publicado en 2009

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

artículo científico publicado en 2007

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

artículo científico publicado en 2010

The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology

artículo científico publicado en 2008

The therapeutic role of dendritic cells in cancer immunotherapy.

artículo científico publicado en 2002

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

artículo científico publicado en 2009

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

artículo científico publicado en 2002

Treatment recommendations for chronic myeloid leukemia

artículo científico publicado en 2014

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

artículo científico publicado en 2015

Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives

artículo científico publicado en 2016

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

artículo científico publicado en 2016

Update on the treatment of disseminated fusariosis: Focus on voriconazole.

artículo científico

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

artículo científico publicado en 2007

Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma

artículo científico publicado en 2005

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

artículo científico publicado en 2011

Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?

artículo científico publicado en 2003

Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group

artículo científico publicado en 2012

p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase

artículo científico publicado en 2003